Literature DB >> 1419465

Selective activation of extrathymic T cells in the liver by glycyrrhizin.

M Kimura1, H Watanabe, T Abo.   

Abstract

Extrathymic pathways for T cell differentiation were recently demonstrated in the liver, intestine and omentum. In this study, glycyrrhizin (GL), a plant extract was investigated as to its effect on extrathymic T cells in the liver of mice. A new method using anti-LFA-1 mAb in conjunction with anti-TCR or -CD3 mAbs to sensitively identify such extrathymic T cells is included. Single injection and repeated injections of GL increased not only the number of total hepatic MNC but also the proportion of intermediate TCR cells, which are extrathymic T cells uniquely seen in the liver. In contrast to other tested reagents (e.g., lymphotoxin and estrogen) that activated the extrathymic T cells and simultaneously induced profound thymic atrophy, GL did not affect regular T cells in the thymus. The present results suggest that the selective activation of extrathymic T cells in the liver might be intimately related to the clinical effects of GL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419465     DOI: 10.1007/bf02171049

Source DB:  PubMed          Journal:  Biotherapy        ISSN: 0921-299X


  15 in total

1.  The differential effect of stress on natural killer T (NKT) and NK cell function.

Authors:  H Oya; T Kawamura; T Shimizu; M Bannai; H Kawamura; M Minagawa; H Watanabe; K Hatakeyama; T Abo
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Prevention of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

3.  Inhibition of human complement by beta-glycyrrhetinic acid.

Authors:  B H Kroes; C J Beukelman; A J van den Berg; G J Wolbink; H van Dijk; R P Labadie
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 4.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 5.  Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.

Authors:  Mark Laws; Yasmin M Surani; Md Mahbub Hasan; Yiyuan Chen; Peiqin Jin; Taha Al-Adhami; Madiha Chowdhury; Aqeel Imran; Ioannis Psaltis; Shirin Jamshidi; Kazi S Nahar; Khondaker Miraz Rahman
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

6.  Effect of compound glycyrrhizin injection on liver function and cellular immunity of children with infectious mononucleosis complicated liver impairment.

Authors:  Zong-xin Cao; Zhong-fang Zhao; Xiu-fen Zhao
Journal:  Chin J Integr Med       Date:  2006-12       Impact factor: 1.978

7.  Glycyrrhizic acid attenuates CCl₄-induced hepatocyte apoptosis in rats via a p53-mediated pathway.

Authors:  Xiao-Ling Guo; Bo Liang; Xue-Wei Wang; Fu-Gang Fan; Jing Jin; Rui Lan; Jing-Hui Yang; Xiao-Chun Wang; Lei Jin; Qin Cao
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

8.  Herbal products: benefits, limits, and applications in chronic liver disease.

Authors:  Anna Del Prete; Antonella Scalera; Maddalena Diana Iadevaia; Agnese Miranda; Claudio Zulli; Laura Gaeta; Concetta Tuccillo; Alessandro Federico; Carmelina Loguercio
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-06       Impact factor: 2.629

9.  Glycyrrhizin as antiviral agent against Hepatitis C Virus.

Authors:  Usman A Ashfaq; Muhammad S Masoud; Zafar Nawaz; Sheikh Riazuddin
Journal:  J Transl Med       Date:  2011-07-18       Impact factor: 5.531

10.  Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: Preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial.

Authors:  Youichi Yanagawa; Masatsune Ogura; Eita Fujimoto; Satoshi Shono; Eriya Okuda
Journal:  Curr Ther Res Clin Exp       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.